Topotecan in Second-Line Therapy of SCLC: Impact on Survival?

Publisher： Karger

E-ISSN： 2296-5262|23|3|9-12

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.23, Iss.3, 2000-05, pp. : 9-12

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Irinotecan in Second-Line Therapy of Metastatic Colorectal Cancer

By  

Oncology Research and Treatment, Vol. 23, Iss. 4, 2000-05 ,pp. : 15-17

Karger

Access to resources Recommend Favorite

Long-Term Survival after Second-Line Therapy with Docetaxel and Carboplatin and Monthly Pamidronic Acid in a Woman with Metastatic Non-Small Cell Lung Cancer

By  

Oncology Research and Treatment, Vol. 29, Iss. 5, 2006-05 ,pp. : 206-208

Karger

Access to resources Recommend Favorite

Docetaxel: Efficacy in First- and Second-Line Therapy of Advanced Breast Cancer

By  

Oncology Research and Treatment, Vol. 23, Iss. 6, 2004-11 ,pp. : 1-3

Karger

Access to resources Recommend Favorite

PSA and Second-Line Therapy of Hormone Refractory Prostate Carcinoma

By  

Urologia Internationalis, Vol. 66, Iss. 3, 2001-04 ,pp. : 131-134

Karger

Access to resources Recommend Favorite

Second-Line Therapy in Refractory Pancreatic Cancer. Results of a Phase II Study

By  

Oncology Research and Treatment, Vol. 32, Iss. 3, 2009-02 ,pp. : 99-102

Karger

Access to resources Recommend Favorite